コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 erihematoma regions (less than two cells per high power field).
2 d) than in the control group (7.92+/-.33 per high-power field).
3 as capillaries containing blue particles per high-power field).
4 le adherence at baseline was uncommon (<2/50 high-power fields).
5 tom improvement and less than 15 eosinophils/high-power field.
6 ty and mast cell numbers were assessed in 20 high-power fields.
7 TAT3+, and CD4+/BNC2+ cells in 5 consecutive high-power fields.
8 single-cell resolution in a series of random high-power fields.
9 h-power fields, or (2) 30 eosinophils in 2-4 high-power fields.
12 (11 points), urine red blood cell count >10/high-power field (3 points), and urine white blood cell
13 hil count less than or equal to 32 cells per high power field (4.55, 1.62-12.78; p=0.0040), rectal bi
14 vs. 21%, P=0.03), contained >9.3 leukocytes/high power field (46.5 vs. 10.5%, P=0.006) or was both P
16 at later time points (mean+/-SEM capillaries/high-power field: 67.6+/-4.7 in control versus 44.1+/-4.
17 sy histology and remissions (<15 eosinophils/high-power field) after dietary therapy and food reintro
19 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03
21 no ganglion cells (0-0.30 ganglion cells per high-power field) and at least mild myenteric inflammati
22 n cell numbers (0.79-0.91 ganglion cells per high-power field) and at least mild myenteric inflammati
24 (P<0.05) in both the normal (1.70+/-0.15 per high-power field) and study groups (2.08+/-0.10 per high
25 (380 +/- 21 polymorphonuclear leukocytes/50 high-power fields) and apoptosis (925% +/- 29% increase
26 ntermediate-level mitotic count (6-10 per 50 high-powered fields) and an intermediate tumor size (6-1
27 (6.4 +/- 1.0 vs 11.4 +/- 1.3 neutrophils per high power field), and less renal apoptosis, as assessed
28 ccurred in many viable hepatocytes (13 cells/high-power field), and nonviable hepatocytes increased s
29 ponds to approximately <5 eosinophils/median high-power field); and endoscopic remission as absence o
30 ochondria in quarter-size grafts were 15 per high power field, and dead cells were less than 1 per hi
31 30 Gardnerella or Prevotella morphotypes per high-power field, as detected by Gram staining of vagina
34 that demonstrates 3 or more erythrocytes per high-powered field before initiating further evaluation
35 trix of the hematoma (17.5 +/- 6.3 cells per high power field) but not in the perihematoma regions (l
37 ular density, as measured by capillaries per high-powered field (c/hpf), was significantly greater in
38 s a peak count of <20 eosinophils/mm(2) in a high-power field (corresponds to approximately <5 eosino
39 ageal biopsy depicts over 20 eosinophils per high-powered field despite the use of aggressive acid bl
40 gic responders, defined by </= 5 eosinophils/high-power field (eos/hpf) (n = 32), underwent systemati
41 d among patients with >/= 15 eosinophils per high-power field (eos/hpf) (OR, 0.79; 95% CI, 0.70-0.88)
42 osis is considered if >or=15 eosinophils per high-powered field (eos/hpf) are detected in mucosal bio
43 cantly, from 114.83 to 73.26 eosinophils per high-power field [(eos/hpf), P = 0.0256], whereas no red
45 an 10% but more than five tumor cells per 10 high power fields (focal) in a subset (7 of 26) of aggre
46 tion in sinusoids (515 +/- 30 neutrophils/50 high power fields) followed by transmigration at 7 h.
47 increased (P<0.05) to 9+/-5 and 5+/-4 per 50 high-power fields for albumin and anionic lipid microbub
48 ree tubules with tubulitis in 10 consecutive high-power fields from the most severely affected areas,
49 of peri-nuclear lysosomes [4.1 x 10,000 per high power field (h.p.f.) +/- 1.9 vs. 2.0 x 10,000 per h
50 th greater than or equal to six CD138+ cells/high power field (hpf) had worse graft survival with a h
52 > or =30 polymorphonuclear cells (PMNL) per high-power field (hpf) on Gram stain (2050 vs. 320 ifu),
53 rmed on all biopsies; CD20+ cell density per high-power field (hpf) was determined for each core.
59 ial sarcoma with less than 10 mitoses per 10 high-power fields (hpf) had a 10-year cancer-specific su
60 oliferative threshold of five mitoses per 10 high-power fields (HPF) was of greater prognostic value
61 otic counts of three mitoses or fewer per 30 high-power fields (HPF), more than three to <or= 15 mito
62 of the difference between 0 to 2 mitoses/10 high-power fields (HPF; 5-year recurrence of 31%) and mo
63 valuated the mean number of Paneth cells per high-powered field (hpf) in 116 duodenal biopsies obtain
64 ur leukocyte, PMN) and macrophage counts per high-powered field (HPF) were performed on fixed section
65 hemotaxis from a baseline of 0.4+/-0.7 cells/high-powered field (hpf; mock-infected) to 21.8+/-2.3 ce
66 +/- 32 polymorphonuclear leukocytes [PMN]/50 high power fields [HPF]) and severe liver injury (plasma
67 h nontolerant grafts (n = 9; 15 vs. 23 cells/high-power field [hpf] [P < .01] and 16 vs. 26 cells/hpf
68 to anti-IL-5 (defined as <15 eosinophils per high-power field [hpf] after mepolizumab therapy), and 7
69 tatistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and
71 mnants were similar (laser, 1.87 +/- 1.05 NV/high-power field [hpf]; drill, 1.92 +/- 1.09 NV/hpf; P =
72 (low grade: no necrosis and < two mitoses/50 high-powered fields [HPF]; or intermediate grade: necros
73 sue neutrophils (20.3 versus 8.6 cells per 5 high-powered fields [HPFs]; P=0.02) and macrophages (6.1
74 he most effective, achieving <15 eosinophils/high-power field in 90.8% and 72.1% of patients, respect
75 IEE (defined as more than 20 eosinophils per high-power field in biopsy specimens) who had undergone
76 tients with EG and 11 +/- 9 eosinophils/x400 high-power field in control subjects (P = 6.1 x 10(-7)).
79 infiltration by immune cells <15 eosinophils/high-power field in esophageal biopsies) for pediatric a
80 ion, the presence of at least 15 eosinophils/high-power field in esophageal biopsy specimens, and exc
81 ophil count was 283 +/- 164 eosinophils/x400 high-power field in patients with EG and 11 +/- 9 eosino
83 d 84.6 +/- 19.7 vs 19.6 +/- 12.9 eosinophils/high-power field in the distal esophagus [P = .04]).
84 number of 30 IgG4-positive plasma cells per high-power field in the orbital tissue is compatible wit
85 ls (65.9 +/- 25.3 vs 1.4 +/- 1.1 eosinophils/high-power field in the proximal esophagus [P = .03] and
86 ation of polymorphonuclear leukocytes per 10 high-power fields in postischemic renal tissue (1111 +/-
87 er dystrophic tubular calcifications per ten high-power fields in the parenteral compared with the en
88 r field, and dead cells were less than 1 per high power field, indicating that depolarization precede
89 m-operated controls (< 10 neutrophils per 20 high-power fields), large numbers of neutrophils were pr
90 tained 180 and 300 IgG4 plasma cells/maximal high-power field, mainly in the deep lamina propria; the
92 tly higher total positive area and intensity/high power field of VCAM-1 expression than did juvenile
93 ek-old mice, 38% (2.5 +/- 3.2 cells per 400x high-power field) of TAMs were GFP-positive, bone marrow
94 e of more than 10 IgG4-positive plasma cells/high power field on endoscopic biopsy of the bile duct w
96 ed a mean of (1) 20 eosinophils or more in 5 high-power fields, or (2) 30 eosinophils in 2-4 high-pow
97 d with hypoxia alone: 23.4 versus 35.0 cells/high-power field (p = 0.01), with no change in other mar
99 te analysis included < or = 2 mitoses per 50 high-power fields (P =.001, P =.002), vascular invasion
100 ignificantly fewer TUNEL-positive nuclei per high-powered field (P<0.01), less DNA fragmentation (ant
103 n chronically rejecting grafts (9+/-1 nuclei/high-powered field, P<0.0001), but the distribution betw
104 een in the lased (4.4 +/- 0.3 arterioles per high power field; p < 0.001 vs. both TMI and sham) compa
105 ed in the EPCM group (4.1 versus 6.2 vessels/high-powered field; P<0.001), and microvascular perfusio
106 positive cells were counted across 10 to 20 high-powered fields per patient by using an automated sy
107 unt were observed in all groups (neutrophils/high-power field): PLV-CVF (20 +/- 2, p = .009); PEEP-CV
108 rge or >/=5 polymorphonuclear leukocytes per high-power field [PMNs/HPF]) were eligible for this doub
109 ctor only group (GV-CVF 47 +/- 2 neutrophils/high-power field), reductions in neutrophil count were o
111 wer field) and study groups (2.08+/-0.10 per high-power field) than in the control group (7.92+/-.33
112 end labeling-positive nuclei (53+/-3 nuclei/high-powered field) than chronically rejecting grafts (9
114 (defined as < 10 dysmorphic erythrocytes per high-power field, the absence of cellular casts, and exc
115 of >/= 2 leukocytes per epithelial cell per high-powered field, the positive predictive values for M
116 d by 1) varying polymorphonuclear leukocytes/high-powered field thresholds and placenta components in
117 was modest for polymorphonuclear leukocytes/high-powered field thresholds of greater than 10 and gre
119 he basis of mitotic rate (< 2 mitoses per 50 high-power fields v higher) and necrosis (present or abs
121 resence of 10 or more mitotic figures per 50 high power fields was an independent predictor of diseas
122 The number of stained blood vessels per high-power field was correlated with the sonographically
123 rowth, acute inflammation (>/= 5 neutrophils/high-power field) was observed in only 40% of patients w
124 mitotic index (<5 or > or =5 mitoses per 50 high-power fields) was developed from 127 patients treat
126 ne 0.6-mm spot is equivalent to two to three high-power fields, we used TMAs to assess levels of hete
129 h 24 or more intraepithelial eosinophils per high-power field were randomly assigned to receive infus
130 large numbers of erythrocytes (> or =100 per high-power field), whereas it was 6.6% (98 of 1,486 spec
131 r-positive (i.e. , more than 100 bacilli per high-power field), while two patient's sputa contained 1
132 tients had 10 or more mitotic figures per 50 high power fields, while 11 had ulceration and/or necros
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。